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It is well known that serum paraoxonase (PON1) plays an important role in the protection of LDL from oxidation. PON1 55
polymorphismiscurrentlyinvestigatedforitspossibleinvolvementincardiovasculardiseases.Theobjectiveofourstudyistoverify
if PON1 55 polymorphism is associated with risk of acute coronary syndrome (ACS) and with biochemical myocardial ischemia
markers, such as troponin I, creatine kinase (CK)-MB, myoglobin, and C-reactive protein. We analysed PON1 55 polymorphism
in a total of 440 elderly patients who underwent an ACS episode: 98 patients aﬀected by unstable angina (UA), 207 AMI (acute
myocardial infarction) patients aﬀected by STEMI (ST elevation), and 135 AMI patients aﬀected by NSTEMI (no ST elevation).
We found that individuals carrying PON1 55 LL genotype are signiﬁcantly more represented among AMI patients aﬀected by
NSTEMI; moreover, the patients carrying LL genotype showed signiﬁcantly higher levels of myoglobin in comparison to LM +
MM carriers patients. Our study suggests that PON1 55 polymorphism could play a role in the pathogenesis of cardiac ischemic
damage. In particular, the signiﬁcant association between PON1 55 LL genotype and the occurrence of a NSTEMI may contribute
to improve the stratiﬁcation of the cardiovascular risk within a population.
1.Introduction
In western developed countries the atherosclerosis-related
diseases, such as cardiovascular disease (CVD), remains so
far the major cause of morbidity and premature death [1].
For this reason, atherosclerotic cardiovascular disease repre-
sents a major public health concern, and many eﬀorts are
addressed to better understand the mechanisms underlying
thisimportantpathology.Theoxidativemodiﬁcationoflow-
density lipoprotein (LDL) in the arterial wall is claimed to
play a central role in the pathogenesis of atherosclerosis.
The oxidative stress is demonstrated to increase the forma-
tion of oxidized macrophages which are, in turn, responsible
fortheoxidationofLDL.Earlystudiesfocusedonatheroscle-
rosis generally considered LDL as the main cause of this
pathology, and the inclusion of statins in clinical practice
has signiﬁcantly improved the quality of life of patients.
The hypothesis of the inﬂammation as an underlying cause
of atherosclerosis has been proposed only recently. For a
long time, these two aspects (lipids and inﬂammation) have
been kept apart, but actually they are the two faces of
the same medal and both should be considered when we2 Journal of Lipids
deal with atherosclerosis. Serum paraoxonase (PON1), an
HDL-associated enzyme, plays an important role in the
protection of LDL from oxidation, and it may attenuate
the development of atherosclerosis [2, 3]. In fact, PON1
hydrolyzes and reduces lipid peroxides in lipoproteins and
in arterial cells. The atheroprotective function of PON1
has been also demonstrated in PON1 knock-out mice,
which exhibited an accelerated atherosclerosis in contrast to
hPON1 transgenic mice where the lesion size was decreased
[4]. PON1 exerts its anti-inﬂammatory properties mainly
hydrolyzing hydrogen peroxide, a major reactive oxygen
species produced under conditions of inﬂammation. The
most studied PON1 gene polymorphisms are due to amino
acid substitutions at position 192 (Gln-Arg) and at position
55 (Leu-Met) in the coding region of the gene. Alleles at
codon 192 (Q and R alleles) and 55 (L and M alleles) in
PON1 locus have been associated with enzymatic activity
and concentration, respectively [5–7]. PON1 192 and 55
polymorphisms have been widely investigated especially
for their possible involvement in the onset or severity of
cardiovascular disease (CVD) [8]. Some studies have found
these two polymorphisms associated with the risk of cardio-
vascular diseases, but others have reported no association
[8]. Until now, a deﬁnitive response about the role of PON1
genetic polymorphisms carried out in CVD does not exist,
and further studies are necessary to better clarify the real
involvement of this gene in cardiovascular pathology. The
purpose of this study is to better explore this issue analysing
the relationship between PON1 55 polymorphism and ACS
(acutecoronarysyndrome).Today,morethanever,theuseof
genetics in the formulation of a diagnosis is a daily need. In
fact, it is widely demonstrated that the traditional resources
available to the clinician, that is, international guidelines
and cardiac enzymes, are insuﬃcient, and this is especially
true in elderly patients where, frequently, the cardiovascular
disease has an unusual onset, often leading to misdiagnosis.
Therefore, studies carried out to ﬁnd new molecular markers
are warranted.
2.MaterialsandMethods
2.1. Sample. The sample enrolled for this study was com-
posedof440elderlypatientsaﬀectedbyACS(acutecoronary
syndrome) (246 males and 194 females, mean age: 79.28 ±
9.94 years) consecutively admitted to the Coronary Care
Unit (CCU) of the Italian National Research Center on
Aging (INRCA) in a consequence of an ACS. Ninety-eight
patients were aﬀected by unstable angina (UA), two hundred
and seven patients were aﬀected by STEMI (ST-elevation
myocardial infarction) and one hundred and thirty-ﬁve
patients were aﬀected by NSTEMI (no ST-elevation myocar-
dial infarction). All patients were considered eligible if they
fulﬁlled the diagnostic criteria for ACS [9].Exclusioncriteria
were severe anemia, cancer, or life expectancy less than 12
months for other severe illness. Patients were then included
in a one-year followup aimed at detecting the cardiovascular
mortality rate (complete followup was available in 67.3% of
the patients, n = 296).
During the hospitalisation the AMI diagnosis was con-
ﬁrmed with instrumental examination, such as coronary
angiography and 2D-ecocardiography. The patients enrolled
inthestudywerestratiﬁedaspatientswithaprevioushistory
of CHD, if the presence of CHD was previously documented,
or patients without a history of CHD, if the current ACS
episode was the ﬁrst CHD manifestation. All subjects gave
their informed consent to the study, which was approved
by the Ethics committee of the INRCA. In all patients we
evaluated arterial blood pressure, total and HDL-cholesterol,
C-reactive protein (CRP), MB fraction of creatine kinase,
measured by mass assay (CK-MB), troponin I (TnI), and
myoglobin levels. Levels of HDL cholesterol were deﬁned as
low if <30mg/dL (0.78mmol/L), and hypercholesterolemia
was deﬁned by 200mg/dL (5.18mmol/L) cholesterol levels
according to WHO guideline [10]. The diagnosis of arterial
hypertension was made according to the 2003 European
Society of Hypertension-European Society of Cardiology
Guidelinesforthemanagementofarterialhypertension[10],
if oﬃce blood pressure was repeatedly >140/90mmHg or if
patients were under antihypertensive treatment. Diagnosis
of type 2 diabetes mellitus was based on revised American
Diabetes Association diagnostic criteria [11].
2.2. Genotyping. DNA was extracted from peripheral blood
mononuclear cells (PBMCs) using phenol/chloroform, ac-
cording to standard procedures [12]. Polymerase chain re-
actionswereperformedusingprimersequencesderivedfrom
published data and speciﬁc for the ampliﬁcation of the
regions surrounding codon 55. The ampliﬁcation reactions
and methodologies have been previously described [13].
2.3. Statistical Analysis. Arterial hypertension, type 2 dia-
betes mellitus, documented history of CHD, hypercholes-
terolemia and low HDL cholesterol were coded as binary
variables on the basis of the presence or absence of these
conditions. Smoking habit was assessed through a question-
naire, and each subject was coded as current or noncurrent
smoker (never and ex-smoker). C-reactive protein (CRP),
MB fraction of creatine kinase (CK-MB), troponin, and
myoglobin levels were natural log transformed before statis-
ticalanalysistoachieveanormaldistribution.Diﬀerencesfor
categorical and continuous variables were assessed by χ2 test
and unpaired t-test, respectively. PON1 55 genotypes were
grouped and analyzed as M+ (LM + MM genotypes) and M
(LL genotype) carriers.
Because diagnoses are deﬁned as 3-level categorical
outcome(UA,STEMI,andNSTEMI),themultinomiallogis-
tic regression was performed to evaluate the relationships
between the ACS and PON1 55 carriers. Odds ratio (OR)
and 95% conﬁdence interval (95% CI) were estimated for
the STEMI and NSTEMI groups with respect to UA patients
(reference group).
The hazard ratios (HRs) with corresponding 95% con-
ﬁdence interval (CI) for the occurrence of one-year follow-
up mortality associated with the following covariates (PON1
55 carriers, age, documented history of CHD, arterial hy-
pertension, smoking habit, hypercholesterolemia, type 2Journal of Lipids 3
Table 1: Baseline clinical and genetics characteristics of 440 elderly
ACS patients.
Characteristics ACS patients (N = 440)
N %
ACS diagnosis: UA (unstable angina) 98 22.3
ACS diagnosis: NSTEMI (no
ST-elevation myocardial infarction) 135 30.7
ACS Diagnosis: STEMI (ST-elevation
myocardial infarction) 207 47.0
Low HDL-cholesterol 133 30.2
No low HDL-cholesterol 307 69.8
Smokers 66 14.9
noncurrent smoker 374 85.1
History of CHD 288 65.4
No history of CHD 152 34.6
Type 2 diabetes mellitus 156 35.5
No Type 2 diabetes mellitus 284 64.5
Arterial hypertension 315 71.6
No arterial hypertension 125 28.4
Hypercolesterolemia 276 62.7
No hypercolesterolemia 164 37.3
Dead 80 27.0
Alive 216 73.0
Table 2: PON1 55 carriers frequencies of 440 ACS patients.
ACS diagnosis M− (LL)
n (%)
M+ (LM + MM)
n (%)
UA (unstable angina) 36 (36.7) 62 (63.3)
NSTEMI (No ST-elevation
myocardial infarction) 70 (51.9) 65 (48.1)
STEMI (ST-elevation
myocardial infarction) 85 (41.1) 122 (58.9)
Total 191 (43.4) 249 (56.6)
χ2 = 6.158, d.f. = 2, P = 0.046: for comparison between ACS diagnosis and
PON55 carriers.
diabetes mellitus, low HDL cholesterol, ACS diagnoses, CRP,
troponin, CK-MB, and myoglobin levels) were estimated
with Cox proportional hazards analysis.
Throughout the study the level of statistical signiﬁcance
was deﬁned by a two-tailed P value <0.05. All the analyses
were performed by tests implemented with the SPSS package
for Windows, version 18 (SPSS, Chicago, Illinois, USA).
3. Results
The baseline clinical characteristics of 440 CHD elderly pa-
tients aﬀected by an ACS are reported in Table 1. PON1
55 carriers frequency distributions, separately considered
on the basis of the diagnosis of UA, STEMI, and NSTEMI
are reported in Table 2. Signiﬁcant diﬀerence among the
three groups of ACS was evident when carrier frequency
distribution was compared (χ2 = 6.158, d.f. = 2 P = 0.046
for carrier frequency). In particular, by the multinomial
logistic regression model, we found that subjects carrying
LL genotype (M carriers) have a higher risk to develop a
NSTEMI, in respect to the other ACS groups (OR: 1.855,
95% CI, 1.090 to 3.156; P = 0.023; UA patients were
considered as the reference group). We then assessed the
mean plasma levels of C-reactive protein and myocardial
ischemia markers (troponin I, CK-MB, and myoglobin)
according to the PON1 55 carriers. We found that among
ACS patients, those who were carriers of the PON1 55
LL genotype displayed signiﬁcantly higher plasma levels
of myoglobin (Table 3). Interestingly, also for the other
biochemical parameters considered (CRP, troponin I, and
CK-MB), we found that LL patients displayed higher levels
in respect to M+ carriers, although not signiﬁcant (Table 3).
The one-year follow-up mortality rate was not signiﬁ-
cantlyassociatedwithPON155carriersneitherwithanyspe-
ciﬁc ACS diagnoses, such as STEMI, NSTEMI, and UA, nor
with history of CHD, smoking habits, hypercholesterolemia,
arterial hypertension, CK-MB levels, or troponin I levels
(data not shown). Conversely, a signiﬁcant association with
mortality rate was found for the following variables: age
(HR: 1.060, 95% CI, 1.020 to 1.102; P = 0.003), history of
type 2 diabetes mellitus (HR: 1.874, 95% CI, 1.104 to 3.183;
P = 0.020),HDLcholesterollevels(HR:1.720,95%CI,1.003
to 2.948; P = 0.049), C-reactive protein (HR: 1.302, 95% CI,
1.073 to 1.580; P = 0.008), and myoglobin levels (HR: 1.511,
95% CI, 1.151 to 1.983; P = 0.003). Moreover, PON1 55M+
and M carriers did not signiﬁcantly correlate with history
of CHD, diabetes mellitus, arterial hypertension, smoking
habits,hypercholesterolemia,andlowHDL-cholesterol(data
not shown).
4. Discussion
Atherosclerosisisamultifactorialdiseaseofgreatcomplexity,
and we are only now beginning to sort out the many el-
ements involved especially in the later stages of the disease.
Accordingly, the main aim of our study was to investigate
the relationship between the PON1 55 polymorphism and
acute coronary syndrome in elderly patients. In the past,
we have extensively analyzed the role of paraoxonase-1 in
healthy elderly people, that is, centenarians, both as genetics
and as activity and mass of the protein (as reviewed in
[14]). The ﬁrst result that we have obtained in this study
is that PON1 55M carriers have a signiﬁcantly diﬀerent
distribution in the three groups of patients, that is, UA,
STEMI, and NSTEMI patients. In particular, subjects car-
rying LL genotype have almost double the risk to develop
an AMI of NSTEMI type. The other important ﬁnding is
that individuals carrying LL genotype displayed signiﬁcantly
higher plasma levels of myoglobin in respect to M+ carriers.
Althoughnotsigniﬁcantly,alsotroponinI,CK-MB,andCRP
levels were higher in LL subjects. All of them are important
biomarkers evaluated in case of patients manifesting the
classical symptoms of an ACS episode. The fact that these
biomarkers were higher in LL patients compared to those
with LM or MM genotype could suggest that they will have
to face a more severe ACS episode. This ﬁnding, to the best4 Journal of Lipids
Table 3: Levels of biochemical parameters according to PON1 55 carriers in ACS patients.
Biochemical parameters PON1 55 M− carriers (LL) PON1 55 M+ carriers (LM + MM) P
CK-MB (μg/L) mean ± SD 78,54 ±118,98 64,76 ±106,22 0.273
Myoglobin (nmol/L) mean ± SD 51.49 ±108.57 33.76 ±67.99 0.044
Troponin I (μg/L) mean ± SD 38,38 ±65,36 26,29 ±61 0.118
C-reactive protein (nmol/L) mean ± S.D 62.19 ±126.86 45.72 ±58.10 0.728
of our knowledge, has not yet been reported in an other
study. In this work the absence of a control group inhibits us
to state if PON1 55 polymorphism could be responsible for
the onset of cardiovascular disease. We can only suggest that
this polymorphism could modulate the pathogenesis and the
seriousness of cardiovascular disease.
Based on the above-mentioned assumptions, we would
expect that the mortality rate would be higher in LL patients
in respect to the other (LM or MM patients). Surprisingly,
the one-year follow-up mortality rate was inﬂuenced by
other variables, such as age, history of type 2 diabetes mel-
litus, HDL-cholesterol levels, C-reactive protein levels, and
myoglobinlevels.ThefactthatPON155polymorphismdoes
not directly inﬂuence the mortality rate could depend by
the fact that subjects with the followup are a subgroup, and
perhapstoofew,orthatthegenotypealonecouldnotexplain
the entire phenomenon. However, it is very interesting to
note that among the variables aﬀecting the mortality rate
we have found myoglobin levels and HDL-cholesterol levels.
The latter is particularly interesting as paraoxonase is a
high-density lipoprotein- (HDL-) associated esterase that
hydrolyses lipoperoxides, and so it could play a role, albeit
in an indirect way.
In the literature, the possible role played by PON1 55
polymorphism, and in particular LL genotype, in the onset
of cardiovascular heart disease (CHD) was extensively inves-
tigated and several authors have found a positive association
between this variant and the cardiovascular pathologies
(reviewed in [8]).
Conversely, the number of the studies that do not con-
sider the onset of the disease but its severity are much less
numerous, at least until now. Perhaps, it depends by the fact
that the genetics of an individual is considered an important
characteristic to determine if the individual could be at risk
of developing a disease in order to make primary prevention.
However,actually,itcouldalsobeimportantoncethedisease
hasoccurredtostratifythesubjectsandtreatthemdiﬀerently
according to the genetic background, focusing on those who
are at increased risk (secondary prevention).
In a recent paper, the authors to ﬁnd the possible can-
didate genes involved in the pathogenesis of coronary ath-
erosclerosis analyzed 1936 tag SNPs within 116 candidate
genes. Interestingly, they found three SNPs associated with
the disease, and one of them (rs854563) is included in an
i n t r o ni nt h es a m er e g i o no fP O N 15 5p o l y m o r p h i s m[ 15].
Another paper analyzed PON1 192 and 55 polymorphisms
in the etiology of CAD. The authors failed to ﬁnd an
association between PON1 55 polymorphism and the onset
of cardiovascular disease, but they found that LL genotype
and L allele were signiﬁcant risk factors in the nonsmoker
group [16]. Accordingly to this study, Malin et al. [17]
also have found that in nonsmoking men the LL genotype
could represent a genetic risk factor for carotid artery
atherosclerotic disease. Unlike previous studies, Robertson et
al. [18] found an higher CHD risk for LL smokers compared
to LL nonsmokers. Although in our study we have not
found an association between smoking habit and PON1 55
polymorphism, in accordance with the former studies we
have found that patients carrying LL genotype have to face
with a more seriously ACS episode. A study in which the
PON1 55/192 haplotype was correlated with the number of
diseased vessels emerged that subjects with PON1 RR/LL
genotype possess an higher number of diseased vessels in
respect to the other genetic variants [19]. The presence of LL
genotypewasalsodemonstratedtobeassociatedwithamore
severedegreeofIR(insulinresistance),suggestingthattheIR
might be the possible missing link between Met-Leu 55 PON
polymorphism and the increased cardiovascular risk [20].
Accordingly,the55Leuallelewasfoundtobeassociatedwith
coronary artery disease only in the subgroup with metabolic
syndrome [21]. Moreover, another paper reported that the
LL homozygous men had more atherosclerotic plaques and
complicated lesions in the common iliac arteries than the
M allele carriers [22]. Conversely, in an Italian study the
PON155 polymorphism wasnotfoundtobeassociatedwith
carotid abnormalities [23].
An important limitation of this study is the lack of
paraoxonase activity, as this could be useful to clarify the role
of this enzyme in CHD and to remove the existing bulk of
conﬂicting results.
Finally, our study suggests that PON1 55 polymorphism
could play a role in the pathogenesis of cardiac ischemic
damage. Hence, the signiﬁcant association between PON1
55 LL polymorphism and the occurrence of a NSTEMI may
contribute to improve the stratiﬁcation of the cardiovascular
risk in UA, NSTEMI, and STEMI being useful in providing a
more accurate assessment of a patient prognosis.
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